We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lovenox Generic Race May Affect Follow-On Biologics
Lovenox Generic Race May Affect Follow-On Biologics
August 24, 2005
The race to launch the first generic version of sanofi-aventis' blockbuster blood thinner Lovenox could ultimately help push the slow-moving debate over follow-on biologics, as one of the key players in the Lovenox chase believes it has figured out how to duplicate biologic drugs by characterizing complex sugars.